<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 13 Apr 2021 10:13:37 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>Claudin 6靶点全梳理</title><link>https://mp.weixin.qq.com/s/nmFIl9rJD5ctouT_8xAfow</link><description></description><content:encoded><![CDATA[Claudin 6靶点全梳理]]></content:encoded><pubDate>Tue, 13 Apr 2021 07:36:13 +0800</pubDate></item><item><title>死亡率降低61%：GM-CSF抗体治疗新冠重症二期临床</title><link>https://mp.weixin.qq.com/s/TzCzgMTztKahhmU6OCeU_A</link><description></description><content:encoded><![CDATA[死亡率降低61%：GM-CSF抗体治疗新冠重症二期临床]]></content:encoded><pubDate>Tue, 13 Apr 2021 07:36:13 +0800</pubDate></item><item><title>AACR：双抗百花齐放</title><link>https://mp.weixin.qq.com/s/YT9_hE3nIdfXUHF6ZyL9eg</link><description></description><content:encoded><![CDATA[AACR：双抗百花齐放]]></content:encoded><pubDate>Mon, 12 Apr 2021 14:57:33 +0800</pubDate></item><item><title>Zymeworks新型三抗技术：PROTECT</title><link>https://mp.weixin.qq.com/s/lAs0dOtR7B18ErzIy-PPqg</link><description></description><content:encoded><![CDATA[Zymeworks新型三抗技术：PROTECT]]></content:encoded><pubDate>Sun, 11 Apr 2021 22:20:55 +0800</pubDate></item><item><title>康柏西普：国际三期临床失败</title><link>https://mp.weixin.qq.com/s/KkQWc1hUtvjojpKVbMXzzw</link><description></description><content:encoded><![CDATA[康柏西普：国际三期临床失败]]></content:encoded><pubDate>Fri, 09 Apr 2021 22:27:58 +0800</pubDate></item><item><title>恒瑞医药申报TSLP抗体，国内第2家</title><link>https://mp.weixin.qq.com/s/Ot6p8tsorm84nZFcVaJUiA</link><description></description><content:encoded><![CDATA[恒瑞医药申报TSLP抗体，国内第2家]]></content:encoded><pubDate>Fri, 09 Apr 2021 22:27:58 +0800</pubDate></item><item><title>康诺亚递表港股IPO，C轮融资后估值7.81亿美元</title><link>https://mp.weixin.qq.com/s/DVGlH0U5d5VMLX_xr4rIYQ</link><description></description><content:encoded><![CDATA[康诺亚递表港股IPO，C轮融资后估值7.81亿美元]]></content:encoded><pubDate>Fri, 09 Apr 2021 00:06:49 +0800</pubDate></item><item><title>腾盛博药递表港股IPO，C轮融资后估值14.55亿美元</title><link>https://mp.weixin.qq.com/s/ViMszDsDIrJfXunCI9bl8g</link><description></description><content:encoded><![CDATA[腾盛博药递表港股IPO，C轮融资后估值14.55亿美元]]></content:encoded><pubDate>Fri, 09 Apr 2021 00:06:49 +0800</pubDate></item><item><title>疫苗百年史</title><link>https://mp.weixin.qq.com/s/8EW5At_YgMC6sy1oBMOynw</link><description></description><content:encoded><![CDATA[疫苗百年史]]></content:encoded><pubDate>Thu, 08 Apr 2021 06:59:59 +0800</pubDate></item><item><title>一型糖尿病新靶点：SerpinB13</title><link>https://mp.weixin.qq.com/s/auFVEqY68-Zn_ZlzF9XbuQ</link><description></description><content:encoded><![CDATA[一型糖尿病新靶点：SerpinB13]]></content:encoded><pubDate>Thu, 08 Apr 2021 06:59:59 +0800</pubDate></item><item><title>肝癌治疗新靶点：HDAC8</title><link>https://mp.weixin.qq.com/s/5TzaWlHD0HvhxESx1XUCEA</link><description></description><content:encoded><![CDATA[肝癌治疗新靶点：HDAC8]]></content:encoded><pubDate>Thu, 08 Apr 2021 06:59:59 +0800</pubDate></item><item><title>磷酸酶靶点：SHP2、PP2A、PRL3......</title><link>https://mp.weixin.qq.com/s/7wzjmH9InDPofuFUdknCJA</link><description></description><content:encoded><![CDATA[磷酸酶靶点：SHP2、PP2A、PRL3......]]></content:encoded><pubDate>Thu, 08 Apr 2021 06:59:59 +0800</pubDate></item><item><title>Nature：胃癌精准治疗新时代</title><link>https://mp.weixin.qq.com/s/GxCPQugRoU9pKDwZj1RB1w</link><description></description><content:encoded><![CDATA[Nature：胃癌精准治疗新时代]]></content:encoded><pubDate>Wed, 07 Apr 2021 06:59:11 +0800</pubDate></item><item><title>天境生物与吉凯基因合作开发双抗</title><link>https://mp.weixin.qq.com/s/WWsSE0HtdqJBrk6dWD4pAg</link><description></description><content:encoded><![CDATA[天境生物与吉凯基因合作开发双抗]]></content:encoded><pubDate>Wed, 07 Apr 2021 06:59:11 +0800</pubDate></item><item><title>抗流感ADC：强生与Cidara达成7.8亿美元合作</title><link>https://mp.weixin.qq.com/s/fhFkZ8uI2xG_xRDh0ue6NA</link><description></description><content:encoded><![CDATA[抗流感ADC：强生与Cidara达成7.8亿美元合作]]></content:encoded><pubDate>Tue, 06 Apr 2021 14:31:15 +0800</pubDate></item><item><title>小分子PD-L1抑制剂：再极医药、红日药业、微芯生物、歌礼制药、东阳光、南京圣和</title><link>https://mp.weixin.qq.com/s/tbknVOk0j9S_ZI1PuAGGlg</link><description></description><content:encoded><![CDATA[小分子PD-L1抑制剂：再极医药、红日药业、微芯生物、歌礼制药、东阳光、南京圣和]]></content:encoded><pubDate>Mon, 05 Apr 2021 07:49:45 +0800</pubDate></item><item><title>自身免疫新靶点：趋化素受体ChemR23</title><link>https://mp.weixin.qq.com/s/6g8gfbHdh1FSihnurCZ8Tg</link><description></description><content:encoded><![CDATA[自身免疫新靶点：趋化素受体ChemR23]]></content:encoded><pubDate>Sun, 04 Apr 2021 07:39:17 +0800</pubDate></item></channel></rss>